If there is worsening glycemic control or failure to achieve targeted glycemic control, significant injection site reactions or allergic reactions, then other antidiabetic therapy should be considered
Novo Nordisk holds semaglutide composition-of-matter and formulation patents expiring between 2031 and 2038 across different jurisdictions, with FlexTouch autoinjector device patents extending GLP-1 competitive protection in the U.S
Glucagon-like peptide-1 (GLP-1) receptor agonists, like Ozempic, mimic a gut hormone that regulates appetite and glucose metabolism, promoting significant weight loss and diabetes management
Researchers also found this drug improved sperm concentration and total sperm count
[DOI] [PubMed] [Google Scholar] 217.Williams LT, Barnes K, Ball L, Ross LJ, Sladdin I, Mitchell LJ